MAPK7 and neoplasm: In line with these observations, ERK5-signaling inhibition has been found to sensitize tumor cells to several antitumor agents, including etoposide [37], trastuzumab [31], tamoxifen [38], crizotinib [39], doxorubicin [40–42], docetaxel [41] and cisplatin [40, 43].